AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03209466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate at 0.125%
Description: Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
Study NCT03209466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator with physiological saline sterile solution
Description: Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
Study NCT03543137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Prototype Mini lozenge
Description: A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study NCT03543137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Mini Lozenge
Description: A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study NCT00465023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Once a day, 5 days a week (Monday-Friday) for 3 weeks.
Study NCT02110095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosure Laser System
Description: Picosure Laser System for the Treatment of Unwanted Tattoos
Study NCT01239823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
Study NCT01239823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise without vibration
Description: Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminopterin
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunomycin
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT03795233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant G3 capsules
Description: After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
Study NCT03795233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin alone
Description: Standard of care will be provided with oral vancomycin therapy.
Study NCT00906516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuradiab in combination with Bevacizumab (Avastin)
Description: Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient.
Study NCT01205464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
Study NCT01205464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
Study NCT01337921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-strain Probiotic
Description: Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
Study NCT01337921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain Probiotic
Description: Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
Study NCT00283153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Affect Recognition Training
Description: A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
Study NCT00283153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stories of Emotional Inference
Description: Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
Study NCT03174028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic pull-through
Description: laparoscopic pull-through
Study NCT03174028 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laparoscopic pull-through
Description: laparoscopic pull-through
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-thioguanine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)
Study NCT00176462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01821703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3045697
Description: Administered as oral solution
Study NCT01821703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as oral solution
Study NCT01821703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Administered as capsule
Study NCT03230760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
Study NCT01821703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsule
Study NCT00556816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: on demand clinic
Description: Outpatient on demand clinic
Study NCT00556816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: conventional outpatient clinic
Study NCT01045694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
Study NCT01045694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid - Triamcinolone Acetonide
Description: Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
Study NCT01045694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Single injection of 1 - 3 mL of 2% Lidocaine
Study NCT03156283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepWell24 Application
Description: An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
Study NCT03127072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Description: The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
Study NCT03127072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy ± target therapy
Description: chemotherapy ± target therapy
Study NCT03127072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy ± target therapy
Description: chemotherapy ± target therapy
Study NCT00852800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: 1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
Study NCT00852800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: 1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
Study NCT03156283 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Plus Activity Monitor
Description: Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
Study NCT04314674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %3 HS bolus
Description: After head fixation %3 HS bolus 3 ml/kg will be administered
Study NCT04314674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %3 HS infusion 20 ml/h
Description: After head fixation %3 HS 20 ml/h infusion will be administered
Study NCT04314674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% mannitol
Description: After head fixation %20 mannitol 0.6 ml/kg will be administered
Study NCT02925546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 milled API without SLS and hypermellose (Tablet C)
Description: This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
Study NCT00284219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation 10Hz
Description: 3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
Study NCT00284219 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnetic stimulation using a special sham coil
Description: Sham stimulation will be given at the same location as the active, with special sham coil.
Study NCT04031989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CorVista Capture
Description: The CorVista System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms developed by CorVista Health. Data collected with the CorVista System during this study will not be used to guide treatment.
Study NCT00583037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Mechanical ventilation controlled by diaphragm electrical activity
Study NCT02606799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb cytokine elimination
Description: Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
Study NCT02709603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine butyl bromide
Description: oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
Study NCT02709603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo; 2 tablets 30 minutes before the procedure
Study NCT02384018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stromal cell
Description: Islet transplantation patients will receive autologous MSCs following islets infusion
Study NCT00959205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARTO 3D
Description: CARTO (3D Electroanatomic imaging)
Study NCT00959205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Conventional fluoroscopically guided activation mapping
Study NCT02632357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Study NCT01229306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation of atrial fibrillation
Study NCT01229306 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ablation
Description: Ablation of atrial fibrillation
Study NCT01659749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metabolic camp
Description: To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
Study NCT01885624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAB08
Description: monoclonal antibody
Study NCT05109923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Herbal Supplement
Description: Weeks 0-2 all participants consumed a placebo lead-in period and weeks 2-6 were intervention weeks. Throughout the 8 weeks (2 weeks placebo lead-in and 6 weeks intervention) participants were asked to consume 2 capsules (multi-ingredient supplement) upon waking in the morning and 2 capsules (multi-ingredient supplement) before bed.
Study NCT05109923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Weeks 0-8 all participants consumed a placebo. Throughout the 8 weeks participants were asked to consume 2 capsules (placebo) upon waking in the morning and 2 capsules (placebo) before bed.
Study NCT01939184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WC3055
Description: 12.5, 25, 50 or 75 mg dose
Study NCT01939184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02903498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: UFT 360mg/m2 qd po d1-14, q3w
Study NCT00940498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (also known as PKI-587)
Description: Intravenous dosing once weekly infusion
Study NCT04119232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social incentives-based program
Description: Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
Study NCT01657292 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oleogel-S10 ointment
Description: Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
Study NCT01657292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10 ointment
Description: Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
Study NCT01657292 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Octenilin® wound gel
Description: Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
Study NCT01657292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octenilin® wound gel
Description: Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
Study NCT00839644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency chest wall oscillation
Description: Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
Study NCT00839644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oscillatory Positive Expiratory Pressure
Description: Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
Study NCT00839644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD&P: Postural drainage and percussion
Description: Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
Study NCT02187068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine administered intravenously
Study NCT01696890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: integrated follow-up
Description: close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
Study NCT01696890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
Study NCT02425059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
Study NCT04419220 — intervention group
Intervention type: OTHER
Intervention: Doppler Ultrasound
Description: Flow measurements using Doppler ultrasound
Study NCT02425059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT01900652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emibetuzumab
Description: Administered IV
Study NCT01900652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered Orally